Home › Products › Ion Channels › Ca2+ Signaling › Voltage-Gated Ca2+ Channels › Blockers

TTA-P2

A Blocker of T-type CaV Channels
Cat #: T-155
  • Lyophilized Powder
  • Bioassay Tested
    • Source Synthetic
    MW: 431
    Purity: >96% (HPLC)
    Form Lyophilized powder.
    Effective concentration 0.05-10 µM.
    Chemical name 3,5-dichloro-N-[1-(2,2-dimethyl-tetrahydro-pyran-4-ylmethyl)-4-fluoro-piperidin-4-ylmethyl]-benzamide. Racemic mixture.
    Molecular formula C21H29Cl2FN2O2.
    CAS No.: 918430-49-6, 1072018-68-8.
    Activity TTA-P2 blocks T-type currents in DRGs with IC50 of 100 nM and 22 nM in thalamocortical and reticular neurons1,2.

      • Choe, W. et al. (2011) Mol. Pharmacol. 80, 900.

      • Dreyfus, F.M. et al. (2010) J. Neurosci. 30, 99.

    Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
    Solubility Up to 25mM in DMSO. Centrifuge all product preparations before use (10000 x g for 1 min).
    Storage of solutions Up to four weeks at 4°C or three months at -20°C.
      • Alomone Labs TTA-P2 inhibits T-type CaV channels heterologously expressed in Xenopus oocytes.
        A. Time course of CaV3.2 peak current amplitude, elicited by 100 ms voltage step from holding potential of -100mV to -30 mV, delivered every 10 seconds. Application of 5 µM TTA-P2 (#T-155) inhibits the CaV3.2 current in a reversible manner (indicated by the horizontal bar). B. Representative current traces before and during application of 5 µM TTA-P2 as indicated.
      • Dreyfus, F.M. et al. (2010) J. Neurosci. 30, 99.
      • Choe, W. et al. (2011) Mol. Pharmacol. 80, 900.

      • TTA-P2 is a novel, potent and selective T-type CaV blocker. In thalamocortical and reticular neurons, it blocks T-type currents with an IC50 of 22 nM without affecting high voltage Ca2+ channels1. In rat DRGs, it blocks T-type currents with an IC50 of 100 nM and stabilizes the channel in the inactive state2.

        TTA-P2 has the potential of acting as an antinociceptive agent2.
    Target T-type CaV channels
    Lyophilized Powder
    receive a 5 mg free trial sample!
    Image & Title TTA-P2
    Alomone Labs TTA-P2 inhibits T-type CaV channels in AZF cells.Bovine adrenal zona fasciculate (AZF) whole cell recordings. Ca2+ currents were recorded in 10 mM Ba2+ in response to voltage steps to -5 mV, applied from a holding potential of -80 mV, before and after superfusion of the cell with 2 μM TTA-P2 (#T-155), (left panel). Concentration-dependent inhibition of CaV3.2 currents by TTA-P2. Values are means ± SE for number of determinations shown in parentheses (right panel).Adapted from Enyeart, J.J. and Enyeart, J.A. (2015) Am. J. Physiol. 308, C899. with permission of the American Physiological Society.
    Last update: 12/05/2019

    TTA-P2 (#T-155) is a highly pure, synthetic, and biologically active compound.

    For research purposes only, not for human use
    Citations
      • Rat DRGs (patch clamp).
        Moutal, A. et al. (2018) Neuroscience 381, 79.
    Related Products